Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.

Also called NCT03016325

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 329 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03016325
  • EudraCT 2016-001685-29
Other papers using this trial's data
  • Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study JACC. Heart failure, 2021-02 DOI, PubMed 33248986

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Czechia, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03016325. Randomized; quadruple masking; primary purpose treatment. Start 2017-01-13 (actual); primary completion 2019-06-23 (actual). Results posted on 2020-08-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure
Acronym
STANDUP AHF
Condition
Heart Failure
Intervention (Drug)
HNO Donor
Intervention (Drug)
Placebo
Lead sponsor
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct03016325
Content hash
fbde69ebdb3cea1151f68fcbfab9f3ea74c07016ef8b2ffece4c0655555239df